LianBio to shut down, return cash to investors

Biotechnology company LianBio will shut down, announcing Tuesday plans to end operations, cut staff and delist from the Nasdaq stock exchange.
The decision follows a strategic review LianBio’s board of directors began in October. They “unanimously decided that winding down operations is the way to realize maximum shareholder value in the current biotech market,” according to the company.